En undersøgelse til evaluering af sikkerhed og effektivitet af Bomedemstat (MK-3543-017)
Et multicenter, åbent udvidelsesstudie, der evaluerer sikkerheden og effektiviteten af Bomedemstat til behandling af deltagere, der er tilmeldt en tidligere Bomedemstat klinisk undersøgelse
The primary purpose of the study is to transition participants into an extension study to collect long-term safety and efficacy data. The study will include participants who are safely tolerating bomedemstat, receiving clinical benefit from its use in estimation of the investigator, and have shown the following criteria:
- Participants from the IMG-7289-202/MK-3543-005 (NCT05223920) study must have received at least 6 months of treatment with bomedemstat;
- Essential thrombocythemia (ET) and polycythemia vera (PV) participants from studies other than IMG-7289-202/MK-3543-005 must have achieved confirmed hematologic response.
No hypothesis testing will be conducted in this study.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-mail: Trialsites@msd.com
Studiesteder
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekruttering
- Royal Prince Alfred Hospital ( Site 1003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61295155720
-
St Leonards, New South Wales, Australien, 2065
- Rekruttering
- Royal North Shore Hospital ( Site 1001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61299264383
-
-
Queensland
-
Buderim, Queensland, Australien, 4556
- Rekruttering
- Sunshine Coast Hematology and Oncology Clinic ( Site 1006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61754790000
-
Southport, Queensland, Australien, 4215
- Rekruttering
- Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61756872712
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Rekruttering
- Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61870740000
-
-
Victoria
-
Clayton, Victoria, Australien, 3168
- Rekruttering
- Monash Health ( Site 1004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +61395956111
-
-
-
-
Hammersmith and Fulham
-
London, Hammersmith and Fulham, Det Forenede Kongerige, W12 0HS
- Rekruttering
- Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442083834340
-
-
Lincolnshire
-
Boston, Lincolnshire, Det Forenede Kongerige, PE21 9QS
- Rekruttering
- Boston Pilgrim Hospital ( Site 3403)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 01205 446311
-
-
London, City of
-
London, London, City of, Det Forenede Kongerige, NW1 2PG
- Rekruttering
- University College London Hospital ( Site 3400)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442034472528
-
London, London, City of, Det Forenede Kongerige, SE1 9RT
- Rekruttering
- Guy's & St Thomas' NHS Foundation Trust ( Site 3401)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +442071884259
-
-
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Rekruttering
- University of Michigan ( Site 6000)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 734-763-4695
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27705
- Rekruttering
- DUHS Duke Blood Cancer Center ( Site 6005)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 919-668-1608
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43210
- Rekruttering
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 888-577-8839
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forenede Stater, 15232
- Rekruttering
- UPMC Hillman Cancer Center ( Site 6004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 412-864-6627
-
-
-
-
-
Hksar, Hong Kong
- Aktiv, ikke rekrutterende
- Queen Mary Hospital ( Site 1601)
-
-
-
-
-
Alessandria, Italien, 15121
- Rekruttering
- Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0131 206440
-
Bologna, Italien, 40138
- Rekruttering
- IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390512143044
-
Varese, Italien, 21100
- Rekruttering
- Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +390332393906
-
-
Tuscany
-
Florence, Tuscany, Italien, 50134
- Rekruttering
- Azienda Ospedaliera Universitaria Careggi ( Site 2700)
-
Kontakt:
- Study Coordinator
- Telefonnummer: +39 0131 206440
-
-
-
-
-
Auckland, New Zealand, 0622
- Aktiv, ikke rekrutterende
- North Shore Hospital-Department of Haematology ( Site 1401)
-
Auckland, New Zealand, 2025
- Aktiv, ikke rekrutterende
- Aotearoa Clinical Trials ( Site 1400)
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Is from a bomedemstat study sponsored by Imago BioSciences, Inc. (a subsidiary of Merck & Co., Inc.) or MSD, and established by the Sponsor as MK-3543-017 ready
- Has received at least 6 months of treatment with bomedemstat in the IMG-7289-202/MK-3543-005 study, while safely tolerating bomedemstat, and receiving clinical benefit from its use in the estimation of the investigator
- ET and PV participants from established feeder studies other than IMG-7289- 202/MK-3543-005 must have achieved confirmed hematologic response, must be safely tolerating bomedemstat, and must be receiving clinical benefit from its use in the estimation of the investigator
- Is not currently on a dose hold
- Participant must be able to swallow oral medication and follow instructions for at-home dosing of bomedemstat
Exclusion Criteria:
- Has received prohibited concomitant medications
- Ongoing or planned participation in another investigational study
- Has noncompliance in prior bomedemstat study receiving <90% of assigned doses excluding suspensions or holds as assigned by the investigator
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Bomedemstat
Participants will receive oral capsules of bomedemstat once daily for up to 10 years, with the starting dose as the same dose that the participant was on at the time of transition from the feeder study. |
10, 15, 20, and 50 mg oral capsules
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of participants with one or more adverse events (AEs)
Tidsramme: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants with AEs will be presented. |
Up to ~10 years
|
|
Percentage of participants who discontinued study treatment due to an AE
Tidsramme: Up to ~10 years
|
An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study treatment due to an AE will be presented. |
Up to ~10 years
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
For participants with ET: Duration of durable clinicohematologic response
Tidsramme: Up to ~10 years
|
For participants who demonstrate durable clinicohematologic response (DCHR) in their feeder study, duration of durable clinicohematologic response (DODCHR) is defined as the time from the first documented evidence of confirmed reduction of platelet and white blood cell (WBC) counts until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events, or disease progression to myelofibrosis (MF), myelodysplastic syndrome (MDS), or acute myeloid leukemia (AML). DODCHR will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of clinicohematologic response
Tidsramme: Up to ~10 years
|
For participants who showed clinicohematologic response in their feeder study, duration of clinicohematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, thrombotic or major hemorrhagic events or disease progression to MF, MDS, or AML, or phlebotomy (PV participants only). The duration of clinicohematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Duration of hematologic response
Tidsramme: Up to ~10 years
|
For participants who showed confirmed hematologic response in their feeder study, duration of hematologic response is defined as the time from the first documented evidence of confirmed reduction of platelet and WBC count until confirmed increase of platelet and WBC counts to above acceptable threshold, or phlebotomy (PV participants only). The duration of hematologic response will be reported. |
Up to ~10 years
|
|
For participants with ET or PV: Percentage of participants with transformation to MF or MDS/AML
Tidsramme: Up to ~10 years
|
Disease Progression is defined as the transformation to post-ET myelofibrosis (ET participants only), post-PV myelofibrosis (PV participants only), spleen volume increase ≥25% (MF participants only), myelodysplastic syndrome, or acute myeloid leukemia as assessed by the investigator. The percentage of participants with transformation to MF or MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF: Percentage of participants with worsening of splenomegaly or transformation to MDS/AML
Tidsramme: Up to ~10 years
|
Spleen volume will be assessed by magnetic resonance imaging (MRI) (or computed tomography [CT] where applicable) at pre-specified timepoints. The percentage of participants with worsening of splenomegaly or transformation to MDS/AML will be reported. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with thrombotic events
Tidsramme: Up to ~10 years
|
Thrombotic events are defined as: new or recurrent acute myocardial infarction; unstable angina; stroke; transient ischemic attack (TIA); deep venous thrombosis (DVT); pulmonary embolism (PE); thrombotic digital ischemia; other thrombotic events such as peripheral limb ischemia or Budd-Chiari syndrome that are assessed to be due to underlying PV; other vascular occlusive events such as symptoms of cardiac, abdominal or peripheral limb ischemia supported by objective evidence of vessel disease and/or ischemia. The percentage of participants with thrombotic events will be presented. |
Up to ~10 years
|
|
For participants with MF, ET, or PV: Percentage of participants with major hemorrhagic events
Tidsramme: Up to ~10 years
|
Hemorrhagic events are defined as: Major Bleeding (MB) Events such as fatal bleeding, and/or symptomatic bleeding in a critical area or organ such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or bleeding causing a fall in hemoglobin level of 2 g/dL or more, or leading to transfusion of 2 or more units of whole blood or red cells; Clinically Relevant Non-Major Bleeding (CRNMB) Events Leading to hospitalization or increased level of care or clinically important, prompting a face-to-face medical evaluation. The percentage of participants with major hemorrhagic events will be presented. |
Up to ~10 years
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Studieleder: Medical Director, Merck Sharp and Dohme LLC
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Hæmatologiske sygdomme
- Blodkoagulationsforstyrrelser
- Knoglemarvssygdomme
- Hæmoragiske lidelser
- Blodpladeforstyrrelser
- Myeloproliferative lidelser
- Knoglemarvsneoplasmer
- Hæmatologiske neoplasmer
- Hemiske og lymfatiske sygdomme
- Trombocytose
- Trombocytæmi, essentiel
- Polycytæmi Vera
- Primær myelofibrose
- Bomedemstat
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 3543-017
- U1111-1294-8621 (Registry Identifier: UTN)
- MK-3543-017 (Anden identifikator: MSD)
- 2023-506996-89-00 (Registry Identifier: EU CT)
- 2023 (U.S. NIH-bevilling/kontrakt)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .